Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects
Scientific Reports · 2024
DOI: 10.1038/s41598-024-75554-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Scientific Reports, 2024. Verfasst von Rui Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China. Hauptthemen laut MEDLINE: Insulin, Long-Acting, Therapeutic Equivalency, Healthy Volunteers, Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Natural Science Foundation of Chongqing,China, the Senior Medical Talents Program of Chongqing for Young and Middle-aged, Municipal Postgraduate Joint Training Base of Chongqing Medical University.
Abstract (Originalsprache)
This study aimed to evaluate the bioequivalence between test and reference insulin degludec (IDeg) and the effects of body composition on pharmacokinetics and pharmacodynamics of IDeg in Chinese healthy volunteers. In this randomized, open-label, crossover trial, 30 healthy Chinese males were assigned to receive a single subcutaneous dose (0.4 IU/kg) of each formulation under 24-h euglycemic hyperinsulinaemic clamp. Body compositions were analysed prior to administration and blood samples were collected at specific times. The 90% of primary pharmacokinetic parameters and 95% of primary pharmacodynamic parameters confidence intervals for the ratio of the least-squares geometric means were all in the range of 80-125%. As the fat content level increases, Cmax, AUC0-12 and GIR-AUC0-24 decreased whereas AUC24-96 increased sequentially. Therefore, the equivalence was demonstrated between test and reference, and in healthy Chinese volunteers, higher levels of adiposity are associated with slower rates of insulin absorption and distribution and the poorer glucose-lowering effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
- Office of academic research, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Phase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China. tcyongwzj@163.com.
Förderung
- the Natural Science Foundation of Chongqing,China
- the Senior Medical Talents Program of Chongqing for Young and Middle-aged
- Municipal Postgraduate Joint Training Base of Chongqing Medical University
- the Scientific Research and Innovation Team Program of Bishan Hospital of Chongqing Medical University
- the Special Research Program for Graduate Student Supervisors of Bishan Hospital of Chongqing Medical University
Zitieren
APA
Su, R., Wan, L., Tao, Y., Zhu, M., Pu, J., Li, Z., Chen, Y., & Tang, C. (2024). Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects. Scientific Reports. https://doi.org/10.1038/s41598-024-75554-3
Vancouver
Su R, Wan L, Tao Y, Zhu M, Pu J, Li Z, et al. Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects. Scientific Reports. 2024. doi:10.1038/s41598-024-75554-3
BibTeX
@article{Su2024,
author = {Su, Rui and Wan, Lei and Tao, Yi and Zhu, Mingxue and Pu, Junliang and Li, Zhongping and Chen, Yuan and Tang, Chengyong},
title = {Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-75554-3}
}
EUVIMED